Meeting
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
Authors
Gerald Steven Falchook
Sarah Cannon Research Institute at HealthONE, Denver, CO
Gerald Steven Falchook , Patricia LoRusso , Jonathan W. Goldman , Anthony B. El-Khoueiry , Anthony W. Tolcher , Yan Xing , Jason Timothy Henry , Bhumsuk Keam , Dong-Wan Kim , Tae-Yong Kim , Hye Ryun Kim , Min Hee Hong , Min Hwan Kim , Dae Ho Lee , SangMi Lee , JuYeun Jeon , John W. Hayslip , Cong Xu , Edward B. Garon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT04762641
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2529)
DOI
10.1200/JCO.2024.42.16_suppl.2529
Abstract #
2529
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
First Author: Timothy A Yap
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.
First Author: Ye Guo
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward